Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

MLA

“Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar Pegol in Neovascular Wet Age-Related Macular Degeneration.” Plus Company Updates, 12 Oct. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.602527815&authtype=sso&custid=ns315887.

APA

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration. (2019, October 12). Plus Company Updates.

Chicago

Plus Company Updates. 2019. “Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar Pegol in Neovascular Wet Age-Related Macular Degeneration,” October 12. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.602527815&authtype=sso&custid=ns315887.